Mesenchymal Stem Cells Market Size Is Poised To Reach .1 Billion By 2028: Grand View Research Inc.

Posted by Mrudula Anil Karmarkar on May 3rd, 2023

The global mesenchymal stem cells market size is expected to reach USD 6.1 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.6% from 2021 to 2028. Mesenchymal stem cells (MSCs) are set to gain popularity among healthcare professionals, to develop novel therapeutics, primarily targeted at the treatment of several immune-mediated disorders. MSCs have been acclaimed effective as a regenerative therapy for skeletal tissue repair and have recently gained traction across modulation of immune cells and endogenous tissues.

Expanding clinical applications of mesenchymal stem cells, strengthening the pipeline of these therapies, along with intensifying market competition are some of the key aspects driving the industry expansion of MSCs. The recent pandemic outbreak of COVID-19 is set to propel the clinical applications and investments done in this market space. For instance, in April 2020, Canada’s The Stem Cell Network (SCN) provided funding of USD 300,000 to the project targeted towards the evaluation of optimal dosage of MSCs, to design an effective therapeutic approach to reduce the impacts of respiratory disorders associated with SARS-CoV-2 infection.

Additionally, as stated by clinicaltrials.gov, 21 clinical trials reportedly incorporated MSCs in the management of COVID-19. Apart from the applications of MSCs in regenerative medicine and tissue engineering, the MSCs serve as a potent therapeutic approach for cancer treatment. As of February 2020, 25 clinical trials have been registered that employ MSCs in the treatment of several cancer indications. This is set to drive the mesenchymal stem cells market (MSCs) market.

Acknowledging the profitable opportunities posed by the market, key industry participants are focused towards initiating technological collaborations to strengthen their market presence. In August 2020, NantKwest Inc. collaborated with Generate Life Sciences Co. to develop a mesenchymal stem cell-based treatment against COVID-19. The latter company is providing with the MSCs derived from donated umbilical cord tissues.

An exponential rise in mesenchymal stem cell (MSC) based research and its implications in the field of regenerative medicine fuel the growth of the market. The constantly evolving landscape of stem cell therapies is also expected to propel investments in the MSC market space; large-scale operational entities are targeting small or emerging players with an operating strategy of acquisition in order to boost their market presence.

To Request Sample Copy of this report, click the link:

https://www.grandviewresearch.com/industry-analysis/mesenchymal-stem-cells-market/request/rs1

The strong pipeline of mesenchymal stem cell-based products coupled with emerging applications of mesenchymal stem cells is anticipated to accelerate the market growth. As of 2019, 10 mesenchymal stem cells based products have received approval from regulatory bodies across the world. Moreover, a substantial number of companies are exploring the potential of MSCs as therapeutics targeted at the treatment of inflammatory disorders, in turn boosting the market growth.

For instance, Takeda/TiGenix phase 3 clinical trial incorporates MSCs for complex perianal fistulas in Crohn's Disease. This is the most successful late-stage clinical trial as of September 2020. These factors are anticipated to bolster the usage of MSC products offered by key market entities, thereby intensifying the market competition. The recent pandemic outbreak of COVID-19 has driven the focus of the scientific community and industry participants towards the development of MSC-based therapeutics. The immunomodulation property of MSCs makes them a potential therapeutic approach to prevent respiratory infection caused by COVID-19.

Mesenchymal Stem Cells Market Report Highlights

• Widespread use of bone marrow derived MSCs in several therapeutic applications has resulted in the segment’s dominance in 2020
• More than 20.0% of clinical trials incorporate bone marrow MSCs, which is set to maintain the segment’s largest revenue share up to 2028
• The cancer indication segment is expected to witness rapid growth through 2021 to 2028, attributed to the emergence of MSCs as a promising vehicle for anti-cancer drugs
• This is attributed to the tumor tropism ability of MSCs and their ability to manage the predestination of tumor cells
• Disease modelling application generated the highest revenue in 2020, owing to several advantages associated with MSCs such as the high capacity of expansion and self-renewal and reduced tumorigenic capacity, which makes them suitable across disease modelling applications
• The kits, media, and reagents segment held a significant revenue share in 2020 owing to the presence of a substantial number of service providers and increasing demand in the market
• The allogeneic segment dominated the market in 2020; Implantation of allogeneic mesenchymal stem cells serves as a promising tool for cell-based therapy
• As of August 2019, more than 200 clinical trials have been reported for use of allogeneic MSCs, which is expected to propel the segment’s revenue generation capacity from 2021 to 2028
• Apart from the availability of advanced research facilities and skilled professionals, favorable government initiatives and high R&D expenditure, active policies pertaining to cell therapies have contributed to the dominance of North America MSCs market in 2020
• For instance, in August 2020, the Centers for Medicare and Medicaid Services proposed new policies that include cellular therapies, wherein, commercial insurance companies support private health plans associated with MSCs
• The key players are engaged in exploring MSC therapy to its highest potential across different emerging applications, contributing to market growth
• For instance, in July 2020, Promedica presented positive results from its study that evaluated the use of allogeneic MSCs in COVID-19 patients. The study was conducted under the U.S. FDA’s Emergency Investigational New Drug (IND) approval

As of July 2020, more than 50 clinical trials have been reported to incorporate MSCs in the development of therapeutics associated with SARS-CoV-2 infection. Additionally, an increasing number of research activities around the development of novel vaccine platforms, involve MSCs. For instance, in June 2020, a group of research professionals in China described a novel approach for designing COVID-19 vaccines based on engineered human MSCs, with promising as well as favorable antibody response.

The majority of the mesenchymal stem cell applications are oriented towards research and clinical settings with comparatively lesser penetration across commercial applications. This is primarily attributed to the lack of standardized and regulated delivery of stem cell therapies; and ethical as well as safety concerns associated with human MSCs. Developments in the regulations and standardization of the mesenchymal stem cell industry are imperative to maintain market growth.

Market players are focused on the expansion of their offerings through extensive R&D and the formation of alliances and partnerships with other major players to sustain their market position. Owing to the recent pandemic of COVID-19, several research and academic research institutes are making focused efforts to develop a treatment regime by using mesenchymal stem cells.

List of Key Players of Mesenchymal Stem Cells (MSCs) Market

• Thermo Fisher Scientific, Inc.
• Cell Applications, Inc.
• Cyagen Biosciences Inc.
• Axol Biosciences Ltd.
• Cytori Therapeutics Inc
• STEMCELL Technologies Inc
• Celprogen Inc
• BrainStorm Cell Therapeutics Inc.
• Stemedica Cell Technologies Inc
• Merck KGaA (MilliporeSigma)
• Smith+Nephew